Lifelong treatment for a lifelong disease

Cerezyme^® (imiglucerase for injection) is not a cure for Gaucher disease; that is, it does not correct the underlying genetic defect. In order to continue to benefit from the treatment, patients must receive intravenous infusions for the rest of their lives, even though they may feel better. Once therapy stops, Gaucher cells may build up again and symptoms may come back.

The enzyme always needs replacing

People with Gaucher disease are deficient in the enzyme glucocerebrosidase, which is responsible for breaking down the fat molecule, glucocerebroside. When administered to patients, Cerezyme therapy acts like glucocerebrosidase and breaks down these fat molecules. If the therapy is stopped, these fat molecules may once again build up, creating more Gaucher cells and a recurrence of signs and symptoms. Please see the important safety information below.

Plan ahead for moves and travel

If an opportunity arises for you or a loved one affected by Gaucher disease to take a vacation; go to camp, attend college, or make a permanent move, Gaucher disease shouldn’t tie you down. But remember, Gaucher disease doesn’t take a break. If you are on ERT and you need to travel, consult with your doctor about arranging infusion services at your destination.

Plan ahead to find a proper facility or qualified health care providers to administer any necessary infusions, as well as to arrange for an appropriate supply of Cerezyme therapy. You may also want to check to see that insurance will cover care for you or an affected family member while traveling. To ensure appropriate treatment, you may want to consider planning care well in advance of travel or a move, as it can sometimes take several months to make all the necessary arrangements.

Genzyme Treatment Support

Genzyme Treatment Support helps patients understand insurance issues, and, in some cases, helps arrange insurance coverage for patients prescribed Cerezyme therapy.

Genzyme Treatment Support case managers can assist patients and families who are planning a trip or a move to make sure that the treatment is covered. For more information, go to Reimbursement support.

Important Safety Information

Side effects related to Cerezyme® (imiglucerase for injection) administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population. Reported side effects include nausea, vomiting, abdominal pain, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Because Cerezyme® therapy is administered by intravenous infusion, reactions at the site of injection may occur: discomfort, itching, burning, swelling or uninfected abscess. Symptoms suggestive of allergic reaction include anaphylactoid reaction (a serious allergic reaction), itching, flushing, hives, an accumulation of fluid under the skin, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), and low blood pressure. Approximately 15% of patients have developed immune responses (antibodies); periodic monitoring by your physician is suggested. Patients should notify their physician immediately if they experience any side effects with treatment. Cerezyme is available by prescription only. For more information, consult your physician. To learn more, please see the full product information (PDF) or contact Genzyme at 1-800-745-4447.